BCRX

9.74

0.71% -0.07

Handel nachbörslich: 9.80 0.06 +0.62%

Biocryst Pharmaceuticals Inc (BCRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BCRX? Forum Prognose

Schlusskurs vom Vortag:

$9.81

Offen:

$9.68

24-Stunden-Volumen:

3.82M

Relative Volume:

0.80

Marktkapitalisierung:

$2.49B

Einnahmen:

$885.72M

Nettoeinkommen (Verlust:

$-457.98M

KGV:

-5.4827

EPS:

-1.7765

Netto-Cashflow:

$293.05M

1W Leistung:

+3.84%

1M Leistung:

+0.00%

6M Leistung:

+44.08%

1J Leistung:

+15.27%

1-Tages-Spanne:

$9.46

$9.7999

1-Wochen-Bereich:

$9.2801

$10.68

52-Wochen-Spanne:

$6.00

$11.22

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Firmenname

Biocryst Pharmaceuticals Inc

Sektor

Healthcare (1080)

Branche

Drug Manufacturers - Specialty & Generic (87)

Telefon

919-859-1302

Adresse

4505 EMPEROR BOULEVARD, DURHAM, NC

Mitarbeiter

435

Twitter

@biocrystpharma

Nächster Verdiensttermin

2026-08-05

Neueste SEC-Einreichungen

BCRX's Discussions on Twitter

Compare BCRX vs TAK, TEVA, HLN, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BCRX Biocryst Pharmaceuticals Inc	9.74	2.71B	885.72M	-457.98M	293.05M	-1.7765
TAK Takeda Pharmaceutical Co Adr	17.63	55.60B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.77	42.81B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.70	43.16B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	73.79	30.39B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	499.73	21.95B	3.17B	1.29B	1.01B	27.09

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-18	Fortgesetzt	Evercore ISI	Outperform
2025-10-15	Fortgesetzt	TD Cowen	Buy
2025-10-01	Herabstufung	Evercore ISI	Outperform → In-line
2025-04-29	Eingeleitet	Cantor Fitzgerald	Overweight
2025-02-25	Eingeleitet	Wedbush	Outperform
2023-11-20	Fortgesetzt	JP Morgan	Overweight
2023-09-18	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2023-08-04	Hochstufung	Jefferies	Hold → Buy
2023-07-13	Hochstufung	BofA Securities	Neutral → Buy
2023-02-22	Hochstufung	Needham	Hold → Buy
2022-11-02	Hochstufung	Evercore ISI	In-line → Outperform
2022-08-05	Herabstufung	Evercore ISI	Outperform → In-line
2022-08-05	Herabstufung	Oppenheimer	Outperform → Perform
2022-04-18	Herabstufung	Barclays	Overweight → Equal Weight
2022-04-11	Herabstufung	BofA Securities	Buy → Neutral
2021-12-10	Eingeleitet	Oppenheimer	Outperform
2021-08-06	Herabstufung	Jefferies	Buy → Hold
2021-08-03	Eingeleitet	Cantor Fitzgerald	Overweight
2021-03-01	Eingeleitet	Cowen	Outperform
2020-09-29	Fortgesetzt	JP Morgan	Overweight
2020-06-17	Eingeleitet	BTIG Research	Neutral
2020-05-05	Hochstufung	Barclays	Equal Weight → Overweight
2019-11-15	Hochstufung	BofA/Merrill	Neutral → Buy
2019-05-24	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2018-11-16	Fortgesetzt	Piper Jaffray	Overweight
2018-08-08	Fortgesetzt	JP Morgan	Overweight
2018-07-17	Hochstufung	BofA/Merrill	Underperform → Neutral
2018-06-22	Eingeleitet	Seaport Global Securities	Neutral
2018-01-02	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2017-12-20	Eingeleitet	Barclays	Equal Weight
2017-09-15	Eingeleitet	RBC Capital Mkts	Sector Perform
2017-09-06	Hochstufung	JP Morgan	Neutral → Overweight
2017-09-06	Hochstufung	Jefferies	Hold → Buy
2017-02-16	Eingeleitet	Ladenburg Thalmann	Buy
2016-08-12	Hochstufung	Piper Jaffray	Neutral → Overweight
2016-08-04	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2016-02-09	Bestätigt	FBR Capital	Outperform
2016-02-09	Herabstufung	JP Morgan	Overweight → Neutral
2016-02-09	Herabstufung	Needham	Buy → Hold

Alle ansehen

Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten

Aug 15, 2026

Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits

Aug 15, 2026

How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares - simplywall.st

Aug 15, 2026

Aug 14, 2026

Discipline and Rules-Based Execution in BCRX Response - Stock Traders Daily

Aug 14, 2026

Biocryst Pharmaceuticals Stock Price Forecast. Should You Buy BCRX? - StockInvest.us

Aug 14, 2026

RA Capital discloses 6.2% BioCryst (BCRX) holding of 15.8M shares - Stock Titan

Aug 14, 2026

Research Analysts Issue Forecasts for BCRX Q4 Earnings - marketbeat.com

Aug 14, 2026

Wedge Capital Management L L P NC Acquires Shares of 380,801 BioCryst Pharmaceuticals, Inc. $BCRX - marketbeat.com

Aug 14, 2026

Aug 13, 2026

BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 5.7%Here's What Happened - marketbeat.com

Aug 13, 2026

Why Did BioCryst Pharmaceuticals (BCRX) Shares Climb After Its Latest Update? - Yahoo Finance

Aug 13, 2026

BioCryst Pharmaceuticals (BCRX) Stock Looks Cheap Even After A 53% Gain - Yahoo Finance

Aug 13, 2026

Bank of America Corp DE Buys 3,556,208 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - marketbeat.com

Aug 13, 2026

Assenagon Asset Management S.A. Buys 120,097 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - marketbeat.com

Aug 13, 2026

Aug 12, 2026

BioCryst (BCRX) Q2 2026 Earnings Call Transcript - The Globe and Mail

Aug 12, 2026

Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High? - Yahoo Finance

Aug 12, 2026

Aug 11, 2026

A Look at BioCryst Pharmaceuticals Inc (BCRX) After 5.1% Gain -- GF Value $12.76 vs Price $10.35 - GuruFocus

Aug 11, 2026

BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6%What's Next? - marketbeat.com

Aug 11, 2026

Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options - Yahoo Finance

Aug 11, 2026

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst? - Yahoo Finance

Aug 11, 2026